Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II

被引:154
作者
Haque, TS
Skillman, AG
Lee, CE
Habashita, H
Gluzman, IY
Ewing, TJA
Goldberg, DE
Kuntz, ID
Ellman, JA [1 ]
机构
[1] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA
[2] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA
[3] Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA
关键词
D O I
10.1021/jm980641t
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A number of single-digit nanomolar, low-molecular-weight plasmepsin II aspartyl protease inhibitors have been identified using combinatorial chemistry and structure-based design. By identifying multiple, small-molecule inhibitors using the parallel synthesis of several focused libraries, it was possible to select for compounds with desirable characteristics including enzyme specificity and minimal binding to serum proteins. The best inhibitors identified have Ki's of 2-10 nM, molecular weights between 594 and 650 Da, between 3- and 15-fold selectivity toward plasmepsin II over cathepsin D, the most closely related human protease, good calculated log P values (2.86-4.56), and no apparent binding to human serum albumin at 1 mg/mL in an in vitro assay. These compounds represent the most potent non-peptide plasmepsin II inhibitors reported to date.
引用
收藏
页码:1428 / 1440
页数:13
相关论文
共 28 条
[1]   Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library [J].
Carroll, CD ;
Patel, H ;
Johnson, TO ;
Guo, T ;
Orlowski, M ;
He, ZM ;
Cavallaro, CL ;
Guo, J ;
Oksman, A ;
Gluzman, IY ;
Connelly, J ;
Chelsky, D ;
Goldberg, DE ;
Dolle, RE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (17) :2315-2320
[2]  
ERICKSON J, COMMUNICATION
[3]  
Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO
[4]  
2-O
[5]  
EWING TJA, UNPUB
[6]   THE MODE OF ACTION AND THE MECHANISM OF RESISTANCE TO ANTIMALARIAL-DRUGS [J].
FOOTE, SJ ;
COWMAN, AF .
ACTA TROPICA, 1994, 56 (2-3) :157-171
[7]   Hemoglobin metabolism in the malaria parasite Plasmodium falciparum [J].
Francis, SE ;
Sullivan, DJ ;
Goldberg, DE .
ANNUAL REVIEW OF MICROBIOLOGY, 1997, 51 :97-123
[8]   ORDER AND SPECIFICITY OF THE PLASMODIUM-FALCIPARUM HEMOGLOBIN DEGRADATION PATHWAY [J].
GLUZMAN, IY ;
FRANCIS, SE ;
OKSMAN, A ;
SMITH, CE ;
DUFFIN, KL ;
GOLDBERG, DE .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (04) :1602-1608
[9]   SMALL WARS, BIG DEFENSE - PAYING FOR THE MILITARY AFTER THE COLD-WAR - WEIDENBAUM,M [J].
GOLD, D .
DEFENCE ECONOMICS, 1993, 4 (04) :365-366
[10]   Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease [J].
Kaldor, SW ;
Kalish, VJ ;
Davies, JF ;
Shetty, BV ;
Fritz, JE ;
Appelt, K ;
Burgess, JA ;
Campanale, KM ;
Chirgadze, NY ;
Clawson, DK ;
Dressman, BA ;
Hatch, SD ;
Khalil, DA ;
Kosa, MB ;
Lubbehusen, PP ;
Muesing, MA ;
Patick, AK ;
Reich, SH ;
Su, KS ;
Tatlock, JH .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (24) :3979-3985